Format

Send to

Choose Destination
Neurobiol Dis. 2014 Jan;61:32-8. doi: 10.1016/j.nbd.2013.08.017. Epub 2013 Sep 17.

Translational PET imaging research.

Author information

1
Merck and Co, WP-42-212, 770, Sumneytown Pike, PO Box 4, West Point, PA19486, USA. Electronic address: richard_hargreaves@merck.com.

Abstract

The goal of any early central nervous system (CNS) drug development program is always to test the mechanism and not the molecule in order to support additional research investments in late phase clinical trials. Confirmation that drugs reach their targets using translational positron emission tomography (PET) imaging markers of engagement is central to successful clinical proof-of-concept testing and has become an important feature of most neuropsychiatric drug development programs. CNS PET imaging can also play an important role in the clinical investigation of the neuropharmacological basis of psychiatric disease and the optimization of drug therapy.

KEYWORDS:

Drug development; Positron emission tomography (PET) imaging; Psychiatry imaging; Target engagement imaging

PMID:
24055214
DOI:
10.1016/j.nbd.2013.08.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center